Startups
Aveni Foundation is committed to expediting the development of gene-targeted therapies for metastati
Overview
Location
United States, California, Santa Monica
Employees
1-10
Phone
+1 323-207-0597
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 23, 2026 | FDA CBER Authorizes Direct Injection of DNG64-CAR-V Gene Therapy into CSF for 2nd Patient with Leptomeningeal Disease | The Cancer Center of Southern California is committed to conducting first in human clinical trials and developing drugs for cancer and neurodegenerative disorders The Aveni Foundation mission is to expedite development of gene-targeted tech... |
| Aug 27, 2026 | FDA Authorizes Injection of Tumor Targeted Gene Therapy Directly into Cerebrospinal Fluid for Leptomeningeal Disease | Artist Illustration of DNG64-CAR-V. DNG64-CAR-V kills not only cancer cells and its blood supply, but also kills cancer associated fibroblasts and converts immune "cold" to immune "hot" tumors. The Aveni Foundation missi... |
| Apr 15, 2024 | DELTAREX-G TUMOR AGNOSTIC THERAPY SHOWS CLINICAL BENEFIT IN CHEMORESISTANT STAGE 4 SARCOMA, PANCREATIC AND BREAST CANCER | Graphic illustration of DRG-101 (DeltaRex-G). This Chimeric Antigen Receptor Vector (CAR-V) displays a Sig targeting peptide on its gp70 env (A), for binding to Signature (Sig) Proteins in the tumor microenvironment [TME] (B), and encodes a... |
| Oct 24, 2023 | AI ANALYSIS SHOWS ENHANCED CCNG1 EXPRESSION IN SARCOMA: A NOVEL BIOMARKER FOR DELTAREX-G CCNG1 INHIBITOR THERAPY | Artist's Illustration of DeltaRex-G that hunts down tumors and nowhere else and kills cancer cells, cancer stem cells and their blood supply. Enhanced Enhanced CCNG1 expression in tumors of patients with osteosarcoma and soft tissue sa... |
| Aug 3, 2023 | DELTAREX-G EXPANDS USFDA AUTHORIZED ACCESS TO BREAST CANCER, PANCREAS CANCER, OSTEOSARCOMA & SOFT TISSUE SARCOMA | Enhanced CCNG1 expression across all cancer types may predict response to DeltaRex-G, a CCNG1 inhibitor. Artist's Illustration of DeltaRex-G that hunts down tumors and nowhere else and kills cancer cells, cancer stem cells and their th... |
| Jul 17, 2023 | UK PHILANTHROPISTS SIMONE AND PAUL COMMINS DONATED GBP 1oo,ooo FOR DELTAREX-G CANCER RESEARCH | Hope and husband Sean on Santa Monica Beach, California Graphic illustration of DeltaRex-G vector. The DeltaRex-G vector has a navigational GPS system (A), for tracking down and binding to abnormal Signature (Sig) proteins in the tumor micr... |
| Jul 7, 2023 | GUSTAVO SANTAOLALLA, TWO-TIME OSCAR WINNING FILM COMPOSER, PERFORMS A UNIQUE SOLO PRESENTATION FOR AVENI FOUNDATION | TWO-TIME OSCAR WINNING FILM AND TELEVISION COMPOSER, PROLIFIC SINGER-SONGWRITER AND VISIONARY PRODUCER GUSTAVO SANTAOLALLA PERFORMS A UNIQUE SOLO PRESENTATION FOR AVENI FOUNDATION The Aveni Foundation mission is to expedite development of g... |
Reviews 0
FAQ about Aveni Foundation
What has the press written about Aveni Foundation?
Parsers VC has collected 8 articles mentioning Aveni Foundation, among them “FDA CBER Authorizes Direct Injection of DNG64-CAR-V Gene Therapy into CSF for 2nd Patient with Leptomeningeal Disease” (Sep 23, 2026) and “FDA Authorizes Injection of Tumor Targeted Gene Therapy Directly into Cerebrospinal Fluid for Leptomeningeal Disease” (Aug 27, 2026).
Is Aveni Foundation still active?
Yes, Aveni Foundation is active; its latest activity on Parsers VC dates from Oct 26, 2026.